Andy Moody

Managing Director
18 years of corporate finance experience, focusing on mid-market private company transactions
Specialises in acquisitions, disposals, buy-outs and finance raising
Worked on deals valued at £10 million to £300 million with significant cross-border elements
Birmingham
@alvarezmarsal
LinkedIn
Copied!
Andy Moody is a Managing Director with Alvarez & Marsal’s Corporate Finance practice in Birmingham.  

With more than 18 years of corporate finance experience, Mr. Moody has advised extensively on private company transactions in the mid-market, including acquisitions, disposals, buy-outs and finance raising. He has worked on deals ranging from £10 million to £300 million that included significant cross-border elements, with counterparties across North America, Europe, India, Japan and Australia.   

Mr. Moody has worked with clients across various industries, including industrial and business services, manufacturing, energy and utilities, building products and software. Mr. Moody led notable recent transactions including the sale of Darwin Group to Portakabin, the sale of Highfield Environmental to Enovert, and the acquisitions of Uni Pol by Doncasters and Sapphire by NTT Data.

Prior to joining A&M, Mr. Moody spent 11 years with Deloitte, working in corporate finance and serving most recently as Director. He focused on supporting Midlands-based private or family-owned businesses and private equity houses on M&A.  

Mr. Moody earned a bachelor’s degree in finance, accounting and management from the University of Nottingham. He is a Chartered Accountant.

 

Insights By This Professional

London, 4 November 2024 – Leading global professional services firm Alvarez & Marsal (A&M) continues to strengthen its Corporate Finance practice in the UK with the appointment of Ian Birch as a Managing Director in Birmingham. At A&M, he will build out the practice’s technology M&A capability across Europe.
Andy Moody joins A&M’s growing M&A practice to serve the mid-market across the Midlands
Latest insights The latest insights from Andy Moody's team
Thought Leadership
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).
Contact me
FOLLOW & CONNECT WITH A&M